semaglutide south africa price A African court has ordered pharmacy group iDexis to stop selling semaglutide-based medicines. The ruling follows a legal challenge by Novo Nordisk, maker of Ozempic and Wegovy. Novo alleged the company Novo Nordisk launches weight-loss drug

In some cases, alternative medications that accomplish the same therapeutic goal without weight-related side effects exist

For people with type 2 diabetes receiving concomitant insulin or sulfonylureas, there is a theoretical risk of hypoglycaemia based on class experience with GLP-1-based therapies

Going from 68 weeks to 104 weeks added only 0.3 percentage points of additional weight loss

Judging from the origin of the reports, LDH deficiency appears to be most common in Japan, where population surveys show a gene frequency of approximately 0.05 for each deficiency, and several mutations have been identified